InvestorsHub Logo
Followers 83
Posts 41801
Boards Moderated 1
Alias Born 01/05/2010

Re: a surfer post# 1912

Sunday, 01/21/2024 7:43:59 PM

Sunday, January 21, 2024 7:43:59 PM

Post# of 22983
Of COURSE you'd run, you're an ill-informed nut job. There are different risks for Covid among the immunocompromised and the elderly, so your narrow junk science fueled view of matters counts for 💩

https://pubmed.ncbi.nlm.nih.gov/35306713/#:~:text=Cutaneous%20vasculitis%20is%20a%20rare,after%20first%20or%20second%20shot.

Cutaneous vasculitis is a rare adverse event to COVID-19 vaccination. It has been observed with mRNA and adenovirus-vector vaccines. IgA vasculitis, lymphocytic and ANCA-associated vasculitis, leukocytoclastic and urticarial vasculitis have been reported. This adverse event can occur after first or second shot.

Most cases run a mild to moderate course. Cornerstone of medical treatment are systemic corticosteroids. Complete remission could be achieved in most patients. Vasculitis may not be considered as a contraindication of vaccination, being uncommonly reported and shows a favorable prognosis. The benefit of the vaccination remains high especially for immunocompromised patients. COVID-vaccine induced vasculitis is important in the differential diagnosis of purpuric and vasculitis disorders.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DJT News